Dalbavancin Biosearch Italia/Versicor

Current Opinion in Investigational Drugs

Volumn 3, Issue 2, 2002, Pages 229-233

  Steiert, Matthias ^a   Schmitz, Franz Josef ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

A 40926; ANTIINFECTIVE AGENT; DALBAVANCIN; LINEZOLID; MDL 62476; MDL 63042; MDL 63246; MDL 63397; PENICILLIN G; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EXPERIMENTAL ANIMAL; GRAM POSITIVE BACTERIUM; HUMAN; NONHUMAN; OTOTOXICITY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DERMATITIS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; TEICOPLANIN; TREATMENT OUTCOME;

EID: 0036231609     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic
2. In vitro activity of semisynthetic glycopeptide amide MDL 63246
3. Pharmacokinetics of MDL 63,246, a new semisynthetic glycopeptide antibiotic, in the rat
4. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci
5. Deacylation of the glycopeptide antibiotic A40926 by Actinoplanes teichomyceticus ATCC 31121
6. The molecular and crystal structure of the glycopeptide A-40926 aglycone
7. A40926 aglycone and pseudoaglycones: Preparation and biological activity
8. Pharmacokinetics of A40926 in rats after single intravenous and subcutaneous doses
9. A40926, a new glycopeptide antibiotic with anti-Neisseria activity
10. Determination of the acyl moieties of the antibiotic complex A40926 and their relation with the membrane lipids of the producer strain
11. Synthesis and antibacterial activity of derivatives of the glycopeptide antibiotic A-40926 N-alkylated at the aminoglucuronyl moiety
12. BI 397: A new developmental semisynthetic glycopeptide antibiotic
13. Synthesis and antibacterial activity of derivatives of the glycopeptide antibiotic A-40926 and its aglycone
14. Semisynthetic glycopeptides: Chemistry, structure-activity relationships and prospects
15. Versicor to present at Hambrecht & Quist 17th Annual Healthcare Conference
16. In vitro activity of the glycopeptide BI 397 against Staphylococcus aureus and Staphylococcus epidermidis
17. Interscience Conference on Antimicrobial Agents and Chemotherapy - 40th Meeting (Part VII), Toronto, Canada
18. V-glycopeptide: Phase 1 single and multiple-dose placebo controlled intravenous safety, pharmacokinetic and pharmacodynamic study in healthy subjects
19. Versicor and Biosearch Italia announce positive data for second generation glycopeptide antibiotic early results show BI-397 (V-Glycopeptide) is bactericidal and rapidly penetrates tissue to eliminate serious staphylococcal infections
20. Biosearch announces the start of phase II trial of dalbavancin, its novel glycopeptide antibiotic
21. Versicor begins phase II trial of dalbavancin, its novel glycopeptide antibiotic
22. American Society of Microbiology - 101st General Meeting (Part II), Orlando, FL, USA
23. American Society of Microbiology - 101st General Meeting (Part III), Orlando, FL, USA
24. Biosearch Italia's ramoplanin designated orphan medicinal product by European Commission; Guarantees 10 years' marketing exclusivity
25. Products and programs
26. Dalbavancin: Phase I single and multiple-dose placebo controlled intravenous safety, pharmacokinetic study in healthy volunteers
27. Efficacy of a single dalbavancin (DA) dose compared with multiple linezolid (LN) doses against penicillin-resistant pneumococci (PRSP) in a lobar pneumonia (LP) model in the immunocompetent rat (IR)
28. Efficacy of a single dalbavancin (DA) dose compared with multiple vancomycin (VA) doses against MRSA in the rat pouch model of infection
29. Stringent audiology assessment in a heavy volunteer study with glycopeptide dalbavancin
30. Activity and spectrum evaluation of dalbavancin (V-glycopeptide and BI397), a novel "glycopeptide" class antimicrobial
31. Versicor announces plans to develop dalbavancin as the first once-weekly injectable antibiotic
32. Biosearch Italia announces plans to develop dalbavancin as the first once-weekly injectable antibiotic
33. Versicor Inc
34. Versicor Inc: Developing exciting and potent new anti-infective drugs
35. Versicor Inc